Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 23: - Two ladies with bruises
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Selective serotonin reuptake inhibitors (SSRIs) mainly affect the platelets by which of the following?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 395 - 402Publisher: Cambridge University PressPrint publication year: 2024
References
Andrade, C. Selective serotonin reuptake inhibitor use in pregnancy and risk of postpartum hemorrhage. J Clin Psychiatry 2022; 83(2):22f14455CrossRefGoogle ScholarPubMed
Anglin, R, Yuan, Y, Moayyedi, P, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 811–19CrossRefGoogle ScholarPubMed
Brazell, C, McClue, SJ, Preston, GC, et al. 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125I]-iodoLSD binding at 5-HT2 receptors. Blood Coagul Fibrinolysis 1991; 2:17–24CrossRefGoogle Scholar
Dalton, SO, Johansen, C, Mellemkjaer, L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163:59–64CrossRefGoogle ScholarPubMed
Halperin, D, Reber, G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9:47–59CrossRefGoogle ScholarPubMed
Jiang, HY, Chen, HZ, Hu, XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13:42–50.e43CrossRefGoogle ScholarPubMed
Maclean, JA, Schoenwaelder, SM. Serotonin in platelets. In Pilowsky, M, ed., Serotonin: The Mediator that Spans Evolution. Boston: Academic Press, 2019, 91–119CrossRefGoogle Scholar
McCloskey, DJ, Postolache, TT, Vittone, BJ, et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151:168–72CrossRefGoogle ScholarPubMed
Meijer, WEE, Heerdink, ER, Nolen, WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164:2367–70CrossRefGoogle ScholarPubMed
Nochaiwong, S, Ruengorn, C, Awiphan, R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med 2022; 54:80–97CrossRefGoogle ScholarPubMed
Perahia, DG, Bangs, ME, Zhang, Q, et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthc Patient Saf 2013; 5:211–19Google ScholarPubMed
Quinn, GR, Hellkamp, AS, Hankey, GJ, et al. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF Trial. J Am Heart Assoc 2018; 7:e008755CrossRefGoogle ScholarPubMed
Renoux, C, Vahey, S, Dell’Aniello, S, et al. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurology 2017; 74:173–80Google ScholarPubMed
Samuel, NG, Seifert, CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. Ann Pharmacother 2017; 51:226–31CrossRefGoogle ScholarPubMed
Song, HR, Jung, Y-E, Wang, H-R, et al. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients. Psychiatry Clin Neurosci 2012; 66:457–9CrossRefGoogle ScholarPubMed